292 related articles for article (PubMed ID: 16292350)
1. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
Kamiyama H; Zhou G; Roizman B
Gene Ther; 2006 Apr; 13(7):621-9. PubMed ID: 16292350
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.
Andreansky S; Soroceanu L; Flotte ER; Chou J; Markert JM; Gillespie GY; Roizman B; Whitley RJ
Cancer Res; 1997 Apr; 57(8):1502-9. PubMed ID: 9108452
[TBL] [Abstract][Full Text] [Related]
3. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
4. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
[TBL] [Abstract][Full Text] [Related]
5. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
Ploug M
Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
[TBL] [Abstract][Full Text] [Related]
6. Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide.
Argnani R; Boccafogli L; Marconi PC; Manservigi R
Gene Ther; 2004 Jul; 11(13):1087-98. PubMed ID: 15057264
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
8. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.
Conner J; Braidwood L; Brown SM
Gene Ther; 2008 Dec; 15(24):1579-92. PubMed ID: 18701918
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells.
Zhou G; Roizman B
J Virol; 2005 May; 79(9):5272-7. PubMed ID: 15827141
[TBL] [Abstract][Full Text] [Related]
10. Targeting human glioma cells using HSV-1 amplicon peptide display vector.
Ho IA; Miao L; Sia KC; Wang GY; Hui KM; Lam PY
Gene Ther; 2010 Feb; 17(2):250-60. PubMed ID: 19812609
[TBL] [Abstract][Full Text] [Related]
11. Use of chimeric nectin-1(HveC)-related receptors to demonstrate that ability to bind alphaherpesvirus gD is not necessarily sufficient for viral entry.
Geraghty RJ; Fridberg A; Krummenacher C; Cohen GH; Eisenberg RJ; Spear PG
Virology; 2001 Jul; 285(2):366-75. PubMed ID: 11437670
[TBL] [Abstract][Full Text] [Related]
12. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
13. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
14. Separation of receptor-binding and profusogenic domains of glycoprotein D of herpes simplex virus 1 into distinct interacting proteins.
Zhou G; Roizman B
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4142-6. PubMed ID: 17360490
[TBL] [Abstract][Full Text] [Related]
15. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
[TBL] [Abstract][Full Text] [Related]
16. Effects of linker-insertion mutations in herpes simplex virus 1 gD on glycoprotein-induced fusion with cells expressing HVEM or nectin-1.
Jogger CR; Montgomery RI; Spear PG
Virology; 2004 Jan; 318(1):318-26. PubMed ID: 14972557
[TBL] [Abstract][Full Text] [Related]
17. Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction.
Zhou G; Ye GJ; Debinski W; Roizman B
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):15124-9. PubMed ID: 12417744
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice.
Li H; Lu H; Griscelli F; Opolon P; Sun LQ; Ragot T; Legrand Y; Belin D; Soria J; Soria C; Perricaudet M; Yeh P
Gene Ther; 1998 Aug; 5(8):1105-13. PubMed ID: 10326034
[TBL] [Abstract][Full Text] [Related]
19. [Oncolytic virus therapy for malignant brain tumors].
Ino Y; Todo T
Brain Nerve; 2009 Jul; 61(7):815-22. PubMed ID: 19618859
[TBL] [Abstract][Full Text] [Related]
20. The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection.
Alfano M; Sidenius N; Blasi F; Poli G
J Leukoc Biol; 2003 Nov; 74(5):750-6. PubMed ID: 12960238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]